Here are seven insights:
1. During this year’s first quarter, Remicade brought in nearly $1.2 billion for Johnson & Johnson.
2. Pfizer has plans to sell its biosimilar, Inflectra, at a 15 percent discount to Remicade.
3. Initially, Wall Street analysts estimated Johnson & Johnson could expect a $1 billion loss in revenue in 2017 due to Inflectra’s market launch.
4. However, other analysts are contesting this figure, with Wells Fargo analyst Lawrence Biegelsen, projecting Johnson & Johnson can expect sales to plummet by $600 million next year.
5. Johnson & Johnson currently sells Remicade at a 30 percent discount off the $1,113.26 list price per 100mg vial. Mr. Biegelsen says Pfizer’s discount will likely be “modest.”
6. Johnson & Johnson also affirms the two drugs are not interchangeable, which may pose a challenge for Pfizer to compete on prices. In an investor note, a Barclays’ analyst weighed in, saying, “From a biosimilar implementation perspective, we believe that a lack of formal guidelines on interchangeability and multiple switch studies [which would be used to convince doctors to switch between drugs] could initially limit Inflectra uptake.”
7. Joaquin Duato, leader of Johnson & Johnson’s pharmaceuticals unit, told The Wallstreet Journal, the company is in the process of creating 10 line extensions on existing products. The company expects the extensions to generate more than $500 million in sales to each of the products and 10 new drugs could have sales surpassing $1 billion.
More articles on devices:
Minimally invasive spine surgery, data gathering, value-based care & more: Key thoughts from NuVasive’s Spine Summit
Transforming SCI treatment — The promise of InVivo’s Neuro-Spinal Scaffold
Beth Israel Deaconess Medical Center jumps into INSPIRE study as 25th clinical site: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
